Evidence map›Paper›PMID 32728856›Full record

ReviewDer Radiologe2020

[Magnetic resonance imaging of the lungs in cystic fibrosis].

P Leutz-Schmidt, M Eichinger, O Sommerburg, M Stahl, S M F Triphan, S Gehlen, H-U Kauczor, M U Puderbach, M A Mall, M O Wielpütz

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Radiologe, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

P Leutz-SchmidtKlinik für Diagnostische und Interventionelle Radiologie, Sektion Pulmonale Radiologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland. patricia.leutz@med.uni-heidelberg.de.
M EichingerKlinik für Diagnostische und Interventionelle Radiologie, Sektion Pulmonale Radiologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland.
O SommerburgTranslational Lung Research Center Heidelberg (TLRC), German Lung Research Center (DZL), Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland.
M StahlTranslational Lung Research Center Heidelberg (TLRC), German Lung Research Center (DZL), Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland.
S M F TriphanKlinik für Diagnostische und Interventionelle Radiologie, Sektion Pulmonale Radiologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland.
S GehlenKlinik für Diagnostische und Interventionelle Radiologie, Sektion Pulmonale Radiologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland.
H-U KauczorKlinik für Diagnostische und Interventionelle Radiologie, Sektion Pulmonale Radiologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland.
M U PuderbachTranslational Lung Research Center Heidelberg (TLRC), German Lung Research Center (DZL), Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland.
M A MallTranslational Lung Research Center Heidelberg (TLRC), German Lung Research Center (DZL), Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland.
M O WielpützKlinik für Diagnostische und Interventionelle Radiologie, Sektion Pulmonale Radiologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Deutschland.
University Hospital Heidelberg · DEGerman Center for Lung Research · DEKlinik und Poliklinik für Nuklearmedizin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

clinical issueDisease severity and mortality in patients with cystic fibrosis (CF) is mainly determined by (progressive) pulmonary lung disease. Early diagnosis and therapy are important and of prognostic value to conserve lung function. STANDARD RADIOLOGICAL

methodsPrimary imaging techniques for lung imaging are x‑ray and computed tomography (CT) to monitor disease severity and regional distribution. METHODICAL INNOVATIONS: Radiation-free imaging techniques such as magnetic resonance imaging (MRI) have gained interest over the last decade in order to prevent radiation damage. PERFORMANCE: The main findings of CF lung disease are airway wall thickening, bronchiectasis, and mucus plugging, which are found in up to 60% of preschool age children. Pleural abnormalities and consolidations are often associated with pulmonary exacerbation. Young CF patients often show a mosaic pattern as functional changes and also perfusion defects can be seen from birth in 50% of CF patients by contrast-enhanced perfusion imaging, and in up to 90% of adult patients, with varying degrees of severity. Dilated bronchial arteries indicate an increased risk for hemoptysis. ACHIEVEMENTS: Proton MRI is the sole imaging technique that can show structural and functional lung changes in one examination. Structured assessment using a scoring system helps to systematically grade the extent and severity of all CF-associated changes.

conclusionsLung MRI for cystic fibrosis has been recently established as a clinical standard examination and is routinely performed at experienced centers. More recently, it has also been used as an endpoint within the framework of clinical studies.

Indexed as

Cystic FibrosisLungMagnetic Resonance ImagingAdultChildChild, PreschoolEarly DiagnosisHumansTomography, X-Ray ComputedContrast mediaCystic fibrosisPerfusion imagingRadiation exposureRespiratory function tests

Identifiers

PMID32728856
OpenAlexW3045762467

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.